IFITM proteins inhibit placental syncytiotrophoblast formation and promote fetal demise.


Journal

Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511

Informations de publication

Date de publication:
12 07 2019
Historique:
received: 25 01 2019
accepted: 23 05 2019
entrez: 13 7 2019
pubmed: 13 7 2019
medline: 24 3 2020
Statut: ppublish

Résumé

Elevated levels of type I interferon (IFN) during pregnancy are associated with intrauterine growth retardation, preterm birth, and fetal demise through mechanisms that are not well understood. A critical step of placental development is the fusion of trophoblast cells into a multinucleated syncytiotrophoblast (ST) layer. Fusion is mediated by syncytins, proteins deriving from ancestral endogenous retroviral envelopes. Using cultures of human trophoblasts or mouse cells, we show that IFN-induced transmembrane proteins (IFITMs), a family of restriction factors blocking the entry step of many viruses, impair ST formation and inhibit syncytin-mediated fusion. Moreover, the IFN inducer polyinosinic:polycytidylic acid promotes fetal resorption and placental abnormalities in wild-type but not in

Identifiants

pubmed: 31296770
pii: 365/6449/176
doi: 10.1126/science.aaw7733
doi:

Substances chimiques

Antigens, Differentiation 0
Apoptosis Regulatory Proteins 0
Gene Products, env 0
IFIT2 protein, human 0
IFIT3 protein, human 0
Interferon Type I 0
Intracellular Signaling Peptides and Proteins 0
Pregnancy Proteins 0
RNA-Binding Proteins 0
leu-13 antigen 0
syncytin 0
Poly I-C O84C90HH2L

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

176-180

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Auteurs

Julian Buchrieser (J)

Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France. julian.buchrieser@pasteur.fr olivier.schwartz@pasteur.fr.
CNRS-UMR3569, Paris, France.

Séverine A Degrelle (SA)

INSERM, UMR-S1139, Faculté de Pharmacie de Paris, Paris, France.
Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Inovarion, Paris, France.

Thérèse Couderc (T)

Institut Pasteur, Biology of Infection Unit, Paris, France.
Institut National de la Santé et de la Recherche Médicale U1117, Paris, France.

Quentin Nevers (Q)

Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France.
CNRS-UMR3569, Paris, France.

Olivier Disson (O)

Institut Pasteur, Biology of Infection Unit, Paris, France.
Institut National de la Santé et de la Recherche Médicale U1117, Paris, France.

Caroline Manet (C)

Mouse Genetics Laboratory, Department of Genomes and Genetics, Institut Pasteur, Paris, France.

Daniel A Donahue (DA)

Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France.
CNRS-UMR3569, Paris, France.

Françoise Porrot (F)

Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France.
CNRS-UMR3569, Paris, France.

Kenzo-Hugo Hillion (KH)

Institut Pasteur, Bioinformatics and Biostatistics Hub, C3BI, USR 3756 IP CNRS, Paris, France.

Emeline Perthame (E)

Institut Pasteur, Bioinformatics and Biostatistics Hub, C3BI, USR 3756 IP CNRS, Paris, France.

Marlene V Arroyo (MV)

Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France.
CNRS-UMR3569, Paris, France.
Department of Biochemistry and Molecular Biophysics and Department of Microbiology and Immunology, Howard Hughes Medical Institute, Columbia University, New York, NY 10032, USA.

Sylvie Souquere (S)

Plateforme de Microscopie Electronique Cellulaire, UMS AMMICA, Gustave Roussy, Villejuif, France.

Katinka Ruigrok (K)

Institut Pasteur, Structural Virology Unit and CNRS UMR3569, Paris, France.

Anne Dupressoir (A)

Unité Physiologie et Pathologie Moléculaires des Rétrovirus Endogènes et Infectieux, CNRS UMR 9196, Gustave Roussy, Villejuif, France.
UMR 9196, Université Paris-Sud, Orsay, France.

Thierry Heidmann (T)

Unité Physiologie et Pathologie Moléculaires des Rétrovirus Endogènes et Infectieux, CNRS UMR 9196, Gustave Roussy, Villejuif, France.
UMR 9196, Université Paris-Sud, Orsay, France.

Xavier Montagutelli (X)

Mouse Genetics Laboratory, Department of Genomes and Genetics, Institut Pasteur, Paris, France.

Thierry Fournier (T)

INSERM, UMR-S1139, Faculté de Pharmacie de Paris, Paris, France.
Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Marc Lecuit (M)

Institut Pasteur, Biology of Infection Unit, Paris, France.
Institut National de la Santé et de la Recherche Médicale U1117, Paris, France.
Paris Descartes University, Department of Infectious Diseases and Tropical Medicine, Necker-Enfants Malades University Hospital, APHP, Institut Imagine, Paris, France.

Olivier Schwartz (O)

Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France. julian.buchrieser@pasteur.fr olivier.schwartz@pasteur.fr.
CNRS-UMR3569, Paris, France.
Vaccine Research Institute, Créteil, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH